Zoek een klinische studie of trial
Andere zoekoptie(s)
38 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Terminated trial
= 
; Gefinancierd door een IRDiRC-lid = 
; Lid van een ERN = 
Nationale klinische studie(s)
VERENIGD KONINKRIJK
Tyne & Wear
NEWCASTLE-UPON-TYNE
EMPOWER: EMesis in Pregnancy - Ondansetron With mEtoclopRamide
Newcastle University
Newcastle Clinical Trials Unit
BELGIË
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STATIN: Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Preeclampsia - BE
CHU Brugmann
Service de médecine foetale / Fetal medicine department
BELGIË
VLAAMS BRABANT
LEUVEN
ASPRE-T: Aspirine versus placebo bij tweelingzwangerschappen voor pre-eclampsiepreventie: een multicenter, gerandomiseerde, dubbelblinde, placebo-gecontroleerde studie - BE
UZ Leuven - Campus Gasthuisberg
Dienst Gynaecologie en Verloskunde / Clinical Department of Obstetrics and Gynaecology
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial - DE
Institution: Information not provided - DE
ITALIË
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial - IT
Institution: Information not provided - IT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial - AT
Institution: Information not provided - AT
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial -ES
Institution: Information not provided - ES
USA
Washington
ADDRESS: NOT PROVIDED - US
Phase II Study of Nicotinamide in Early Onset Preeclampsia
Institution: Information not provided - US
VERENIGD KONINKRIJK
Greater London
LONDON
MCRN007: An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome (phase II) - UK
University College London Hospitals, NHS Foundation Trust
Endocrinology Department
ZWEDEN
Region Stockholm
SOLNA
Effects of Nitrate-rich Beetroot Juice in Pregnant Women With High Blood Pressure - SE
Karolinska Institutet
Department of Physiology and Pharmacology (FYFA)
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
REAL 8: A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature - AT
Institution: Information not provided - AT
SPANJE
Comunidad Valenciana
VALENCIA
hSCU-PRP: Umbilical cord plasma for treating endometrial pathologies (thin endometrium / Ash erman's syndrome/ endometria atrophy)
Hospital Universitario y Politécnico La Fe
Servicio de Obstetricia y Ginecología
BELGIË
OOST-VLAANDEREN
GENT
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway - BE
Ghent University Hospital - UZ Gent
Ghent University Hospital
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - CA
DUITSLAND
Baden-Württemberg
ULM
An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation -DE-
Zentrum für Seltene Erkrankungen am Universitätsklinikum Ulm
Zentrum für Seltene Erkrankungen (ZSE) ULM
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -DE
Institution: Information not provided - DE
FRANKRIJK
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -FR
Institution: Information not provided - FR
FRANKRIJK
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome -FR
Institution: Information not provided - FR
FRANKRIJK
OCCITANIE
TOULOUSE
OXYJEUNE : Effects of Intranasal Administrations of Oxytocin on Behavioural Troubles, Hyperphagia and Social Skills in Children With Prader-Willi Syndrome Aged From 3 to 12 Years (Phase III)
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi
FRANKRIJK
OCCITANIE
TOULOUSE
Long-term Interventional Follow-up Study up to 4 Years of Age of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial and Comparison With an Untreated Cohort of Children With Prader-Willi Syndrome -FR
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi
ITALIË
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome - IT
Institution: Information not provided - IT
NEDERLAND
Zuid-Holland
ROTTERDAM
Dutch Growth Hormone Cohort study in children with Prader-Willi syndrome: Long-term effects on growth, body composition, activity level and psychosocial development
Stichting Kind en Groei
NEDERLAND
Zuid-Holland
ROTTERDAM
Behandeling met N-acetylcysteïne voor skin picking gedrag in kinderen en jongvolwassenen met PWS: een gerandomiseerde, gecontroleerde, cross-over studie
Stichting Kind en Groei
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome -ES
Institution: Information not provided - ES
SPANJE
Madrid
MADRID
A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
USA
Washington
ADDRESS: NOT PROVIDED - US
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
Institution: Information not provided - US
VERENIGD KONINKRIJK
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - GB
VERENIGD KONINKRIJK
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -GB
Institution: Information not provided - GB
VERENIGD KONINKRIJK
Merseyside
LIVERPOOL
Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome
Fazakerley Hospital
University Hospital Aintree - Diabetes and Endocrinology
VERENIGD KONINKRIJK
West Midlands
BIRMINGHAM
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic
Multinationale klinische studie(s)
AUSTRALIË
Victoria
ADDRESS: NOT PROVIDED - AU
A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruritus. - TURRIFIC Protocol Version 8
Institution: Information not provided - AU
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
Effect of folic acid supplementation in pregnancy on preeclampsia - Folic Acid Clinical Trial (FACT)A randomized, double-blind, placebo-controlled, Phase III, international multi-centre study of 4.0 mg of Folic Acid supplementation in pregnancy for the prevention of preeclampsia - Folic Acid Clinical Trial (FACT)
Institution: Information not provided - CA
VERENIGD KONINKRIJK
Greater London
LONDON
ASPRE-T: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: a multicenter, randomised, double-blind, placebo-controlled trial.
King's College Hospital
Harris Birthright Research Centre for Fetal Medicine
HONGARIJE
Dél-Dunántúl
ADDRESS: NOT PROVIDED - HU
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome.
Institution: Information not provided - HU
NEDERLAND
Utrecht
ADDRESS: NOT PROVIDED - NL
Global Growth Hormone Study in Adults With Prader-Willi Syndroom
Institution: Information not provided - NL
USA
Washington
ADDRESS: NOT PROVIDED - US
An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
Institution: Information not provided - US
USA
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation.
Institution: Information not provided - US
VERENIGD KONINKRIJK
Greater London
LONDON